Shanghai Junshi Biosciences Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 4.28%

Shanghai Junshi Biosciences Co Ltd (688180) has an Asset Resilience Ratio of 4.28% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Shanghai Junshi Biosciences Co Ltd for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥500.77 Million
≈ $73.28 Million USD Cash + Short-term Investments

Total Assets

CN¥11.69 Billion
≈ $1.71 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2014–2024)

This chart shows how Shanghai Junshi Biosciences Co Ltd's Asset Resilience Ratio has changed over time. See shareholders equity of Shanghai Junshi Biosciences Co Ltd for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Shanghai Junshi Biosciences Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 688180 market cap overview.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥500.77 Million 4.28%
Total Liquid Assets CN¥500.77 Million 4.28%

Asset Resilience Insights

  • Limited Liquidity: Shanghai Junshi Biosciences Co Ltd maintains only 4.28% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Shanghai Junshi Biosciences Co Ltd Industry Peers by Asset Resilience Ratio

Compare Shanghai Junshi Biosciences Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 3.28%
Summit Therapeutics PLC
NASDAQ:SMMT
Biotechnology 0.00%
Argen-X
F:1AE
Biotechnology 25.67%
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
Biotechnology 0.21%
R&G PharmaStudies Co. Ltd. A
SHE:301333
Biotechnology 35.96%
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
Biotechnology 79.48%
Innovita Biological Technology Co. Ltd. A
SHG:688253
Biotechnology 70.49%
Sunmax Biotechnology Co Ltd
TWO:4728
Biotechnology 10.53%

Annual Asset Resilience Ratio for Shanghai Junshi Biosciences Co Ltd (2014–2024)

The table below shows the annual Asset Resilience Ratio data for Shanghai Junshi Biosciences Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 3.99% CN¥430.51 Million
≈ $63.00 Million
CN¥10.80 Billion
≈ $1.58 Billion
+3.99pp
2020-12-31 0.00% CN¥17.00K
≈ $2.49K
CN¥8.01 Billion
≈ $1.17 Billion
0.00pp
2019-12-31 0.00% CN¥17.00K
≈ $2.49K
CN¥4.42 Billion
≈ $647.14 Million
-0.13pp
2018-12-31 0.13% CN¥5.52 Million
≈ $807.16K
CN¥4.26 Billion
≈ $622.98 Million
-11.96pp
2017-12-31 12.09% CN¥147.43 Million
≈ $21.57 Million
CN¥1.22 Billion
≈ $178.48 Million
-20.42pp
2016-12-31 32.50% CN¥373.47 Million
≈ $54.65 Million
CN¥1.15 Billion
≈ $168.14 Million
-38.21pp
2014-12-31 70.71% CN¥235.44 Million
≈ $34.45 Million
CN¥332.94 Million
≈ $48.72 Million
--
pp = percentage points

About Shanghai Junshi Biosciences Co Ltd

SHG:688180 China Biotechnology
Market Cap
$4.52 Billion
CN¥30.91 Billion CNY
Market Cap Rank
#3835 Global
#626 in China
Share Price
CN¥40.38
Change (1 day)
+0.20%
52-Week Range
CN¥28.43 - CN¥48.80
All Time High
CN¥151.00
About

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of malignant tumors, neurological, autoimmune, chronic metabolic, nervous system, and infectious diseases in the People's Republic of China. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of … Read more